|
1
|
Thapa B, Fazal S, Parsi M and Rogers HJ:
Myeloproliferative Neoplasms. In: StatPearls [Internet]. StatPearls
Publishing, Treasure Island, FL, 2023.
|
|
2
|
Barbui T, Thiele J, Gisslinger H,
Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A and Tefferi A:
The 2016 WHO classification and diagnostic criteria for
myeloproliferative neoplasms: Document summary and in-depth
discussion. Blood Cancer J. 8(15)2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tefferi A and Pardanani A:
Myeloproliferative Neoplasms: A contemporary review. JAMA Oncol.
1:97–105. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tiu RV, Gondek LP, O'Keefe CL, Elson P,
Huh J, Mohamedali A, Kulasekararaj A, Advani AS, Paquette R, List
AF, et al: Prognostic impact of SNP array karyotyping in
myelodysplastic syndromes and related myeloid malignancies. Blood.
117:4552–4560. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Broséus J, Alpermann T, Wulfert M,
Florensa Brichs L, Jeromin S, Lippert E, Rozman M, Lifermann F,
Grossmann V, Haferlach T, et al: Age, JAK2(V617F) and SF3B1
mutations are the main predicting factors for survival in
refractory anaemia with ring sideroblasts and marked
thrombocytosis. Leukemia. 27:1826–1831. 2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Liu HD, Ahn KW, Hu ZH, Hamadani M,
Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald MR,
Sabloff M, et al: Allogeneic hematopoietic cell transplantation for
adult chronic myelomonocytic leukemia. Biol Blood Marrow
Transplant. 23:767–775. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Cattaneo D, Croci GA, Bucelli C, Tabano S,
Cannone MG, Gaudioso G, Barbanti MC, Barbullushi K, Bianchi P,
Fermo E, et al: Triple-Negative essential thrombocythemia:
Clinical-pathological and molecular features. A single-center
cohort study. Front Oncol. 11(637116)2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Accurso V, Santoro M, Mancuso S,
Napolitano M, Carlisi M, Mattana M, Russo C, Di Stefano A, Sirocchi
D and Siragusa S: The essential thrombocythemia in 2020: What we
know and where we still have to dig deep. Clin Med Insights Blood
Disord. 13(2634853520978210)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Go RS: Myeloproliferative disorders with
coexisting BCR-ABL translocation and JAK2(V617F) mutation.
Leukemia. 21(2051)2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Malhotra J, Kremyanskaya M, Schorr E,
Hoffman R and Mascarenhas J: Coexistence of myeloproliferative
neoplasm and plasma-cell dyscrasia. Clin Lymphoma Myeloma Leuk.
14:31–36. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Stoll DB, Peterson P, Exten R, Laszlo J,
Pisciotta AV, Ellis JT, White P, Vaidya K, Bozdech M and Murphy S:
Clinical presentation and natural history of patients with
essential thrombocythemia and the Philadelphia chromosome. Am J
Hematol. 27:77–83. 1988.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ceylan C, Ozyilmaz B, Kirbiyik O, Ugur MC
and Ozer O: JAK2V617F, CALR and MPL515L/K mutations and
plateletcrit in essential thrombocythemia: A single centre's
experience. Int J Clin Pract. 75(e13834)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Oppliger Leibundgut E, Haubitz M,
Burington B, Ottmann OG, Spitzer G, Odenike O, McDevitt MA, Röth A,
Snyder DS and Baerlocher GM: Dynamics of mutations in patients with
essential thrombocythemia treated with imetelstat. Haematologica.
106:2397–2404. 2021.PubMed/NCBI View Article : Google Scholar
|
